InvestorsHub Logo
Followers 21
Posts 2717
Boards Moderated 0
Alias Born 01/27/2022

Re: Jasbg post# 424203

Wednesday, 05/15/2024 7:02:55 AM

Wednesday, May 15, 2024 7:02:55 AM

Post# of 427141
Jasbg, did you even read my post? I realize English is not your first language, but I'm not sure how you arrived at your conclusion from what I posted. Read it again, very slowly this time.

I said..."Omega-3s broadly seem to have pharmacological potential similar to that of a drug, but a risk profile more akin to a nutrient." It's too bad that Amarin can't get this point across. "- referring to Vascepa!

My point was that I appreciated how she framed the benefit of Omega-3's (strong efficacy, very low risk), but wished that Amarin would take that same tack with Vascepa.

JR, I really dont know what to think of this post ?
-----------------------------------------------------------------

Do you 'at all' - understand the Reduce-It trial - based on Vascepa - times 8 purified EPA ?

How can you seriously talk about general Omega 3 oil products in this context ?
------------------------------

You say you own 200k AMRN shares - representing an FDA approved medicine for greatly reducing risk for CDV patients !

I fail to understand how you can promote the endless number of ordinary OTC fish-oil products on the internet - being invested this BIG in AMRN and Vascepa ?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News